# Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

> **NCT06749054** · PHASE2 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 12 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Oral Lenacapavir
- **DRUG:** Subcutaneous Lenacapavir
- **DRUG:** Optimized Background Regimen (OBR)

## Key facts

- **NCT ID:** NCT06749054
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-26
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06749054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06749054, "Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06749054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*